Evidence map›Paper›PMID 40512322›Full record

ArticleClinical and experimental nephrology2025

The epidemiology of encapsulating peritoneal sclerosis in an era of biocompatible neutral peritoneal dialysis solution in Japan.

Yukio Maruyama, Nanae Matsuo, Yudo Tanno, Masato Ikeda, Keitaro Yokoyama, Masaaki Nakayama, Takashi Yokoo

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yukio MaruyamaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi Minato-ku, Tokyo, 105-8461, Japan. maruyama@td5.so-net.ne.jp.ORCID http://orcid.org/0000-0002-5602-8104
Nanae MatsuoDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi Minato-ku, Tokyo, 105-8461, Japan.
Yudo TannoDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi Minato-ku, Tokyo, 105-8461, Japan.
Masato IkedaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi Minato-ku, Tokyo, 105-8461, Japan.
Keitaro YokoyamaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi Minato-ku, Tokyo, 105-8461, Japan.
Masaaki NakayamaDivision of Research Management, St Luke's International University, Tokyo, Japan.
Takashi YokooDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi Minato-ku, Tokyo, 105-8461, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEncapsulating peritoneal sclerosis (EPS) is one of the most serious complications of peritoneal dialysis (PD). Although the incidence and severity of EPS are said to have decreased with the widespread adoption of biocompatible neutral PD solutions, the overall prevalence in Japan remains unclear.

methodsWe extracted patients with EPS from 2012 to 2022 using the Web-based Analysis of Dialysis Data Archives (WADDA) system of the Japanese Society for Dialysis Therapy. EPS was defined as present in patients with a history of PD treatment presenting with symptoms of ileus due to intestinal adhesion. Patients with only ascites, calcification of the intestine or bloody PD effluent were not defined as having EPS. We collected data from patients with EPS including sex, age, dialysis modality, dialysis duration, cause of end-stage kidney disease and cause of death among deceased patients.

resultsApproximately 700 patients with EPS were identified (60-65% males; mean age, 61-66 years), accounting for 5% of the sum of PD patients and patients on other dialysis modalities with experience of PD. The majority received hemodialysis or hemodiafiltration, with a mean dialysis duration of 12-14 years. The crude death rate was approximately 5% and death from ileus was more frequent than in the total cohort of dialysis patients.

conclusionsThe present study using a nationwide database of Japanese dialysis patients revealed a large number of patients with EPS. We plan to conduct a longitudinal study to clarify outcomes for patients with EPS.

Indexed as

Dialysis SolutionsKidney Failure, ChronicPeritoneal DialysisPeritoneal FibrosisAgedDatabases, FactualFemaleHumansIncidenceJapanMaleMiddle AgedPrevalenceTime FactorsDialysis SolutionsBiocompatible neutral solutionCrude death rateHemodiafiltrationHemodialysisIleusWeb-based system

Identifiers

PMID40512322

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.